Cynosure Group LLC Cuts Stock Position in Eli Lilly and Company $LLY

Cynosure Group LLC cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 33.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 1,361 shares of the company’s stock after selling 673 shares during the period. Cynosure Group LLC’s holdings in Eli Lilly and Company were worth $1,039,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the company. Braun Bostich & Associates Inc. boosted its holdings in shares of Eli Lilly and Company by 2.5% in the second quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock valued at $411,000 after acquiring an additional 13 shares in the last quarter. Rise Advisors LLC lifted its position in Eli Lilly and Company by 1.8% in the second quarter. Rise Advisors LLC now owns 732 shares of the company’s stock valued at $571,000 after purchasing an additional 13 shares during the period. Occidental Asset Management LLC boosted its holdings in Eli Lilly and Company by 0.7% in the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock valued at $1,533,000 after purchasing an additional 13 shares in the last quarter. New Insight Wealth Advisors boosted its holdings in Eli Lilly and Company by 3.4% in the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock valued at $307,000 after purchasing an additional 13 shares in the last quarter. Finally, Dash Acquisitions Inc. increased its position in Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after purchasing an additional 13 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Key Stores Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and commentary cite Lilly’s long‑term growth setup — strong GLP‑1 franchise, a deep obesity pipeline and AI/innovation tailwinds — that support multi‑year revenue upside and justify bullish ratings. 3 Reasons Why Lilly (LLY) Is a Great Growth Stock
• Positive Sentiment: Several investment writeups highlight Lilly as a top stock for 2026 and note the company’s recent revenue trajectory and guidance, which support longer‑term earnings expectations. 3 Top Ranked Stocks to Buy for 2026 (LLY, WFRD, PGY)
• Neutral Sentiment: Market pieces debate whether now is a buy, hold or sell after a sharp 3‑month gain; these narratives can increase short‑term volatility but don’t change fundamentals immediately. LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?
• Neutral Sentiment: Sector/idea pieces list Lilly among AI‑enabled medtech/biotech names to watch — a thematic positive over time but unlikely to drive intraday moves. Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026
• Negative Sentiment: Market reaction to Novo Nordisk’s U.S. launch of an oral Wegovy pill is the headline pressure point — investors are pricing in faster share loss and margin competition in the obesity/weight‑loss market. Novo Nordisk Stock Jumps as it Battles Eli Lilly for Market Share with $149 Wegovy Pill Launch
• Negative Sentiment: Legal and political risk intensified as Indiana’s Attorney General filed a lawsuit against Lilly over insulin pricing — this raises potential headline/legal costs and regulatory scrutiny. Indiana sues Eli Lilly over insulin prices
• Negative Sentiment: Short‑term selling pressure is also reflected in quick market checks and opinion pieces suggesting profit‑taking or repositioning after Lilly’s strong run and rising valuation multiples. Eli Lilly Stock (LLY) Falls 4% as Rival Novo Nordisk Begins Selling Obesity Pill in U.S.

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent analyst reports. Truist Financial raised their price target on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a report on Wednesday, November 19th. UBS Group reiterated a “neutral” rating on shares of Eli Lilly and Company in a research report on Thursday, December 18th. Cantor Fitzgerald restated an “overweight” rating on shares of Eli Lilly and Company in a research report on Monday, December 1st. Berenberg Bank increased their price target on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a report on Tuesday, December 2nd. Finally, Loop Capital set a $950.00 price objective on shares of Eli Lilly and Company in a report on Monday, November 10th. Five equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $1,161.27.

Eli Lilly and Company Stock Down 3.6%

Shares of NYSE LLY opened at $1,041.78 on Tuesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,111.99. The company has a market capitalization of $984.88 billion, a PE ratio of 50.97, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The firm’s 50-day moving average is $1,017.48 and its two-hundred day moving average is $853.10.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the previous year, the firm posted $1.18 EPS. The company’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is presently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.